3HP-2827 / 3H Pharma - LARVOL DELTA

A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations (clinicaltrials.gov) - P1 | N=130 | Not yet recruiting | Sponsor: 3H (Suzhou) Pharmaceuticals Co., Ltd. | Initiation date: Jun 2024 ➔ Jun 2025

Metastases • Trial initiation date • Oncology • Solid Tumor

A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations (clinicaltrials.gov) - P1/2 | N=130 | Recruiting | Sponsor: 3H (Suzhou) Pharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial primary completion date: Mar 2028 ➔ Jun 2028

Enrollment open • Metastases • Trial primary completion date • Oncology • Solid Tumor

A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations (clinicaltrials.gov) - P1/2 | N=130 | Not yet recruiting | Sponsor: 3H (Suzhou) Pharmaceuticals Co., Ltd.

Metastases • New P1/2 trial • Oncology • Solid Tumor

3HP-2827-high selective inhibitor of FGFR2, a best-in-class therapy for FGFR2‑driven solid tumors (AACR 2024) - "In the ICC PDX model, 3HP-2827 also induces the regression of pemigatinib-resistant tumors. 3HP-2827 is well tolerated in the toxicology studies, and no hyperphosphatemia or tissue mineralization is observed at 150 mg/kg/kg/day in rats and 120 mg/kg/day in dogs. The data support that 3HP-2827, a potential to be a best-in-class selective FGFR2 inhibitor, will be studying clinically at the beginning of 2024."

Endometrial Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • FGFR1 • FGFR2 • FGFR3

A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumours With FGFR2 Alterations (clinicaltrials.gov) - P1 | N=130 | Not yet recruiting | Sponsor: 3H (Suzhou) Pharmaceuticals Co., Ltd.

New P1 trial • Oncology • Solid Tumor